Horizon Pharma plc (42)

Browse by Contract Category

Contracts

Horizon Therapeutics Public Limited Company 2014 Non-Employee Equity Plan, as amended, and Form of Option Agreement, Form of Stock Option Grant Notice, Forms of Restricted Stock... (Filed With SEC on November 3, 2021)
Horizon Therapeutics Public Limited Company Amended and Restated 2018 Equity Incentive Plan (assumed from Viela Bio, Inc.) and Form of RSU Award Grant Notice and Form of Award... (Filed With SEC on November 3, 2021)
License Agreement, dated April 16, 1999, by and among Saul Brusilow, M.D., Brusilow Enterprises, Inc. and Horizon Therapeutics, LLC (as successor in interest to Medicis... (Filed With SEC on February 24, 2021)
Settlement Agreement and First Amendment to License Agreement, dated August 21, 2007, by and among Saul Brusilow, M.D., Brusilow Enterprises, Inc., and Horizon Therapeutics, LLC... (Filed With SEC on February 24, 2021)
Agreement and Plan of Merger, dated January 31, 2021, by and among Horizon Therapeutics USA, Inc., Teiripic Merger Sub, Inc., Viela Bio, Inc. and solely for purposes of Sections... (Filed With SEC on February 1, 2021)
Description of securities registered under Section 12 of the Exchange Act of 1934 (Filed With SEC on February 26, 2020)
Horizon Therapeutics Public Limited Company Amended and Restated 2020 Equity Incentive Plan and Form of Option Agreement, Form of Stock Option Grant Notice, Forms of Restricted... (Filed With SEC on November 3, 2021)
Executive Employment Agreement, effective as of March 15, 2021, by and among Horizon Therapeutics Public Limited Company, Horizon Therapeutics USA, Inc. and Elizabeth H.Z. Thompson (Filed With SEC on May 5, 2021)
Third Supplemental Indenture, dated March 15, 2021, by and between Viela Bio, Inc. and U.S. Bank National Association (Filed With SEC on May 5, 2021)
License Agreement, dated August 12, 1998, by and among Mountain View Pharmaceuticals, Inc., Duke University and Horizon Therapeutics Ireland DAC (as successor in interest to... (Filed With SEC on February 24, 2021)
API Supply Agreement, dated November 3, 2010, by and between Cambrex Profarmaco Milano and Horizon Therapeutics Ireland DAC (as successor in interest to Raptor Therapeutics Inc.... (Filed With SEC on November 2, 2020)
Incremental Amendment and Lender Joinder Agreement, dated August 17, 2020, by and among JP Morgan Chase Bank, N.A., as an incremental revolving lender and as an issuing bank,... (Filed With SEC on November 2, 2020)
Development and Manufacturing Services Agreement, dated June 10, 2015, by and between AGC Biologics A/S (formerly known as CMC Biologics A/S) and Horizon Therapeutics Ireland DAC... (Filed With SEC on November 2, 2020)
Amendment No. 3 to Commercial Supply Agreement, dated July 30, 2020, by and between AGC Biologics A/S (formerly known as CMC Biologics A/S) and Horizon Therapeutics Ireland DAC (Filed With SEC on November 2, 2020)
Underwriting Agreement, dated August 6, 2020, by and among Horizon Therapeutics Public Limited Company and the several underwriters named therein (Filed With SEC on August 10, 2020)
Horizon Therapeutics Public Limited Company 2020 Equity Incentive Plan and Form of Option Agreement, Form of Stock Option Grant Notice, Forms of Restricted Stock Unit Agreement... (Filed With SEC on August 5, 2020)
Second Supplemental Indenture, dated April 23, 2020, by and among Horizon Properties Holding LLC, Curzion Pharmaceuticals, Inc. and U.S. Bank National Association (Filed With SEC on May 6, 2020)
First Supplemental Indenture, dated November 19, 2019, by and between HZNP Finance Limited and U.S. Bank National Association (Filed With SEC on May 6, 2020)
Amendment No. 2 to API Supply Agreement, effective as of January 17, 2018, by and between Cambrex Profarmaco Milano and Horizon Therapeutics Ireland DAC (Filed With SEC on February 26, 2020)
Amendment to Supply Agreement, effective as of November 30, 2018, by and between NOF Corporation and Horizon Therapeutics Ireland DAC (Filed With SEC on February 26, 2020)
Amendment No. 2 to Commercial Supply Agreement, dated December 18, 2019, by and between AGC Biologics A/S (formerly known as CMC Biologics A/S) and Horizon Therapeutics Ireland DAC (Filed With SEC on February 26, 2020)
License Agreement, effective as of June 15, 2011, by and among F. Hoffmann-La Roche Ltd, Hoffman-La Roche Inc. and Horizon Therapeutics Ireland DAC (as successor in interest to... (Filed With SEC on February 26, 2020)
Separation Agreement, dated January 23, 2020, by and between Horizon Therapeutics USA, Inc. and Shao-Lee Lin, M.D., Ph.D (Filed With SEC on February 26, 2020)
Executive Employment Agreement, effective as of November 1, 2019, by and among Horizon Therapeutics Public Limited Company, Horizon Therapeutics USA, Inc. and Andy Pasternak (Filed With SEC on November 6, 2019)
Release and Waiver of Claims of Robert F. Carey, dated as of September 18, 2019 (Filed With SEC on November 6, 2019)
Mutual Settlement, Release and Media License Agreement, effective as of December 21, 2016, by and between River Vision Development Corp. and Boehringer Ingelheim... (Filed With SEC on November 6, 2019)
Amendment No. 1 to Commercial Supply Agreement, dated May 15, 2019, by and between AGC Biologics A/S (formerly known as CMC Biologics A/S) and Horizon Pharma Ireland Limited (Filed With SEC on August 7, 2019)
Horizon Pharma Public Limited Company Non-Employee Director Compensation Policy, as amended (Filed With SEC on August 7, 2019)
Indenture dated as of July 16, 2019 by and between Horizon Pharma USA, Inc., the guarantors party thereto and U.S. Bank National Association, as trustee (Filed With SEC on July 16, 2019)
Commercial Supply Agreement, effective as of December 18, 2018, by and between Catalent Indiana, LLC and Horizon Pharma Ireland Limited (Filed With SEC on May 8, 2019)
Executive Employment Agreement, effective as of May 1, 2019, by and between Horizon Pharma USA, Inc. and Jeffery Kent, M.D., FACP, FACG (Filed With SEC on May 8, 2019)
Commercial Supply Agreement, effective as of February 14, 2018, by and between CMC Biologics A/S, dba AGC Biologics and Horizon Pharma Ireland Limited (Filed With SEC on May 8, 2019)
Horizon Therapeutics Public Limited Company Amended and Restated 2014 Equity Incentive Plan, and Form of Option Agreement, Form of Stock Option Grant Notice, Forms of Restricted... (Filed With SEC on May 8, 2019)
License Agreement, effective as of June 15, 2011, by and among F. Hoffmann-La Roche Ltd, Hoffman-La Roche Inc. and River Vision Development Corp, as amended through Amendment No.... (Filed With SEC on May 8, 2019)
Exclusive License Agreement, dated December 5, 2012, by and between Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center and River Vision Development Corp (Filed With SEC on May 8, 2019)
Horizon Therapeutics Public Limited Company 2014 Non-Employee Equity Plan, as amended, and Form of Option Agreement, Form of Stock Option Grant Notice, Forms of Restricted Stock... (Filed With SEC on May 8, 2019)
Underwriting Agreement, dated March 6, 2019, by and among Horizon Pharma Public Limited Company and the several underwriters named therein (Filed With SEC on March 7, 2019)
Rights Agreement, dated as of February 28, 2019, between Horizon Pharma Public Limited Company and Computershare Trust Company, N.A (Filed With SEC on February 28, 2019)
Seventh Supplemental Indenture, dated November 15, 2018, by and between Horizon Medicines LLC and U.S. Bank National Association (Filed With SEC on February 27, 2019)
Amended and Restated Executive Employment Agreement, effective as of August 1, 2018, by and among Horizon Pharma, Inc., Horizon Pharma USA, Inc. and Geoffrey M. Curtis (Filed With SEC on February 27, 2019)
Horizon Pharma Public Limited Company Non-Employee Director Compensation Policy, as amended (Filed With SEC on February 27, 2019)
Third Supplemental Indenture, dated November 15, 2018, by and between Horizon Medicines LLC and U.S. Bank National Association (Filed With SEC on February 27, 2019)